Journals / Turkish Journal of Gastroenterology / 2020 / Cilt: 31 - Sayı: 3

Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey

Pages
221–233
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In regions where antibiotic resistance rates are elevated, performing antibioticsusceptibility tests may lead to effective eradication treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: The aim of this study was to assess the clinical and sociodemographic risk factors of Helicobacter pylori infectionand antibiotic resistance in the eastern Black Sea region of Turkey.Materials and Methods: In total, 344 patients with dyspeptic symptoms who completed an extended questionnaire were enrolled in thestudy.
📊
Key Findings & Data:Susceptibility of H.pylori strains was assessed by agar dilution (amoxicillin, tetracycline, metronidazole, levofloxacin) and E-test (clarithromycin) methods.Results: The H. pylori positivity rate was 40.4% (139/344).
💡
Conclusion & Impact:In regions where antibiotic resistance rates are elevated, performing antibioticsusceptibility tests may lead to effective eradication treatment.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background/Aims: The aim of this study was to assess the clinical and sociodemographic risk factors of Helicobacter pylori infectionand antibiotic resistance in the eastern Black Sea region of Turkey.Materials and Methods: In total, 344 patients with dyspeptic symptoms who completed an extended questionnaire were enrolled in thestudy. Diagnosis of H. pylori infection was made by rapid urease test, histopathological investigation, and culture. Susceptibility of H.pylori strains was assessed by agar dilution (amoxicillin, tetracycline, metronidazole, levofloxacin) and E-test (clarithromycin) methods.Results: The H. pylori positivity rate was 40.4% (139/344). Logistic regression analysis indicated that age and the presence of duodenalulcer were independent risk factors associated with H. pylori positivity (odds ratio (OR): 0.96, 95% CI: 0.93–0.99, p=0.013; OR: 5.42, 95%CI: 1.96–14.98, p=0.001, respectively). Of 104 H. pylori-positive cultures, 43 strains (41%) were susceptible to all antibiotics, whereas 61(59%) were resistant to at least one antibiotic. H. pylori resistance rates were 34% for levofloxacin, 31.1% for metronidazole, 28.2% forclarithromycin, 2.9% for amoxicillin, and 1% for tetracycline. Logistic regression analysis indicated that previous use of clarithromycinwas the only independent risk factor for H. pylori resistance (OR: 6.25, 95% CI: 1.59-24.52, p=0.009).Conclusion: An understanding of the risk factors for H. pylori positivity and antibiotic resistance in an extended anamnesis may affecttreatment choice and facilitate H. pylori eradication. In regions where antibiotic resistance rates are elevated, performing antibioticsusceptibility tests may lead to effective eradication treatment.

🔖

Cite This Article

ERKUT, M., UZUN, D. Y., KAKLIKKAYA, N., FİDAN, S., YOĞUN, Y., COŞAR, A. M., AKYILDIZ, E., TOPBAŞ, M., ÖZGÜR, O., ARSLAN, M. (2020). Sociodemographic characteristics and clinical risk factors of Helicobacter pylori infection and antibiotic resistance in the Eastern Black Sea region of Turkey. Turkish Journal of Gastroenterology, Cilt: 31 - Sayı: 3, 221–233. https://ajindex.com/articles/408723

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-25. [Crossref] 2. Hunt RH, Xiao SD, Megraud F, et al. World Gastroenterology Organisation Global Guideline: Helicobacter pylori in developing countries. J Dig Dis 2011; 12: 319-26. [Crossref] 3. Brown LM, Thomas TL, Ma JL, et al. Helicobacter pylori infection in rural China: demographic, lifestyle and environmental factors. Int J Epidemiol 2002; 31: 638-45. [Crossref] 4. Sinha SK, Martin B, Sargent M, McConnell JP, Bernstein CN. Age at acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter 2002; 7: 76-85. [Crossref] 5. Malfertheiner P, Megraud F, O’Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection the Maastricht V/Florence Consensus Report. Gut 2017; 66: 6-30. [Crossref] 6. Kearney DJ, Brousal A. Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients. Dig Dis Sci 2000; 45: 265-71. [Crossref] 7. Kadayifci A, Buyukhatipoglu H, Cemil Savas M, Simsek I. Eradication of Helicobacter pylori with triple therapy: an epidemiologic analysis of trends in Turkey over 10 years. Clin Ther 2006; 28: 1960- 6. [Crossref] 8. Gisbert JP. “Rescue” regimens after Helicobacter pylori treatment failure. World J Gastroenterol 2008; 14: 5385-402. [Crossref] 9. O’Connor A, Gisbert J, O’Morain C. Treatment of Helicobacter pylori infection. Helicobacter 2009; 14: 46-51. [Crossref] 10. Boyanova L, Ilieva J, Gergova G, et al. Evaluation of clinical and socio-demographic risk factors for antibacterial resistance of Helicobacter pylori in Bulgaria. J Med Microbiol 2009; 58: 94-100. [Crossref] 11. Megraud FH. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-84. [Crossref] 12. Osato, MS, Reddy R, Reddy SG, Penland, RL, Malaty HM, Graham, DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-20. [Crossref] 13. McMahon BJ, Hennessy TW, Bensler, JM, et al. The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections. Ann Intern Med 2003; 139: 463-9. [Crossref] 14. Boyanova L, Il